Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.
LAMPGEN ANALYSIS
Why it matters
The allosteric BCR::ABL1 inhibitor moved into the newly diagnosed setting, with molecular response supporting accelerated approval.
What research teams should watch
Standardize BCR::ABL1 reporting on the International Scale and record test timing, adherence and treatment interruptions.
PRIMARY RECORDS